Clinical effects of prior trastuzumab on combination eribulin mesylate plus trastuzumab as first-line treatment for human epidermal growth factor receptor 2 positive locally recurrent or metastatic breast cancer: results from a Phase II, single-arm, multicenter study

Shannon Puhalla,1 Sharon Wilks,2 Adam M Brufsky,1 Joyce O’Shaughnessy,3 Lee S Schwartzberg,4 Erhan Berrak,5 James Song,5 Linda Vahdat6 1Department of Hematology and Oncology, University of Pittsburgh Medical Center, Pittsburgh, PA, 2Department of Hematology Oncology, US Oncology-Cancer Car...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Puhalla S, Wilks S, Brufsky AM, O'Shaughnessy J, Schwartzberg LS, Berrak E, Song J, Vahdat L
Format: article
Langue:EN
Publié: Dove Medical Press 2016
Sujets:
Accès en ligne:https://doaj.org/article/b81856979c9e4f40a00c19cd8d7c905a
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!